REVOLUTIONIZING PERSONALIZED ORAL DRUG FORMULATION THROUGH CUTTING-EDGE 3D PRINTING TECHNOLOGIES

In oral drug formulations, three-dimensional (3D) printing appeared as a revolutionary 
technology for the creation of customised, flexible and complex dosage forms to conquer key 
restrictions of conventional pharmaceutical manufacturing. Based on digital models, enabling 
precise control over drug distribution, porosity and release characteristics, 3D printing 
generates dosage forms layer-by-layer, which is an additive manufacturing. Some of the 
important technologies, like fused deposition modelling (FDM), stereolithography, selective 
laser sintering (SLA), binder jetting, and direct powder extrusion (DPE), have acquired 
critical attention for their capacity to fabricate tablets with sustained or multi-phase profiles. 
Spritam is the first 3D printed oral drug that was approved by the FDA. For future products, 
it validates the clinical potential of the technologies and generates a regulatory precedent. For 
pediatric and geriatric populations, researchers focus on personalised dosage forms by 3D 
technology for controlled and targeted drug delivery. Decentralisation manufacturing and 
decreased dependency on large-scale batch processes are supported by 3D printing with 
speed up the adoption by continuing innovation in printing methods, regulatory frameworks, 
and biocompatible polymers. Eventually, 3D printing is expected to revolutionise oral drug 
delivery by allowing personalised patient-centric pharmaceutical care and efficient.